Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07632157 · ClinicalTrials.gov registry record · Phase 3
MAGNEsium With meToprolol for Rate Control In Atrial Fibrillation
A Phase 3 study, sponsored by Wake Forest University Health Sciences.
- Not yet
- Registry status
- Phase 3
- Development phase
- 196
- Enrollment target
NCT07632157 is a Phase 3 study that has not yet begun recruiting, run by Wake Forest University Health Sciences. The registered enrollment target is 196 participants.
The verdict
NCT07632157, a Phase 3 study, has not yet begun recruiting, sponsored by Wake Forest University Health Sciences.
- NOT YET RECRUITING
- Registry status
- Phase 3
- Development phase
- 196 participants
- Enrollment target
Study Summary
The purpose of this research study is to find out if the use of magnesium in addition to Metoprolol, a rate controlling medication that you would be offered in the Emergency Department today unrelated to this study, will help reduce your high heart rate (rapid ventricular response).
Interventions
- DRUG Saline (0.9% NaCl)
- DRUG Magnesium Sulfate 2g
- DRUG Magnesium Sulfate 4g
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 196 participants |
| Start Date | 2026-10 |
| Est. Completion | 2028-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07632157
The ClinicalTrials.gov registry entry for NCT07632157 describes a study currently listed as not yet recruiting, categorized as Phase 3. The registered enrollment target is 196 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Saline (0.9% NaCl) is the first listed.
NCT07632157 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07632157 about?
NCT07632157 is a clinical study titled "MAGNEsium With meToprolol for Rate Control In Atrial Fibrillation". The purpose of this research study is to find out if the use of magnesium in addition to Metoprolol, a rate controlling medication that you would be offered in the Emergency Department today unrelated to this study, will help reduce your high heart rate (rapid ventricular response).
What is the current status of trial NCT07632157?
This trial is currently not yet recruiting. It is a Phase 3 study. The enrollment target is 196 participants. The study started on 2026-10. Estimated completion is 2028-12.
What interventions are being tested in trial NCT07632157?
The interventions under investigation include: Saline (0.9% NaCl) (DRUG), Magnesium Sulfate 2g (DRUG), Magnesium Sulfate 4g (DRUG).
Who is sponsoring clinical trial NCT07632157?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.